Navigation Links
Compound from marine bacteria shows potential as multiple myeloma therapy

An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell.

The experimental compound, NPI-0052, has been found to block or inhibit cancer cells' proteasomes from working effectively. The proteasome work as a cell's "garbage disposal," chewing up and disposing of old, unwanted proteins. With their proteasome jammed, cells die from the backup of damaged proteins.

"Proteasome inhibition is a key therapeutic target and bortezomib (Velcade tm) was the first in a new class of compounds in multiple myeloma. NPI-0052 is a novel proteasome inhibitor with a chemical structure and action that is distinct from bortezomib, and has the promise of being even more effective for patients," says Kenneth Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber, and senior author of the report.

The compound will be moved into Phase I clinical trials in early 2006, say officials of Nereus Pharmaceuticals in San Diego, the developer of NPI-0052. The compound will be tested as a single agent and subsequently in combination with other treatments.

Multiple myeloma is a currently incurable cancer of the bone marrow that causes a plunge in the production of vital red and white blood cells. Although relatively rare, it is the second most common type of blood cancer and accounts for 11,000 deaths annually in the United States. Bortezomib, approved by the Food and Drug Administration in 2003 for relapsed myeloma patients and subsequently for patients who have received at least one prior treatment, demonstrated in clinical trials that it extended the time to disease progression and also improved survival.

Though less toxic than conventional chemotherapy, bortezomib does have
'"/>

Source:Dana-Farber Cancer Institute


Page: 1 2 3

Related biology news :

1. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
2. Newly Discovered Compound Blocks Known Cancer-Causing Protein
3. Compounds in plastic packaging act as environmental estrogens altering breast genes
4. Compound might defeat African sleeping sickness, clinical trial beginning this month
5. Compound from Chinese medicine shows promise in head and neck cancer
6. Anti-cancer Compound In Beer Gaining Interest
7. Compound in dairy products targets diabetes
8. Compound eyes, evolutionary ties
9. Sequencing of marine bacterium will help study of cell communication
10. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
11. UN environmental agency steps up battle against marine pollution

Post Your Comments:
(Date:11/19/2009)... with an unwieldy name: 4-hydroxybutyrate (4-HB). ...-rape drug. , Now, a team of Ohio and Michigan ...B is metabolized by the body. "This is new and imp...ssor and chair of biological sciences at Michigan ...rch team. "It may provide new clues on how to cou...
(Date:11/19/2009)...ing the genetic instructions inside corn, one of t... of the most complex sequences of DNA ever analyze... David Schwartz, who was one of more than 100 auth...The maize genome is a true maze full of confusing... sequencers for years," says Schwartz. , Publica...
(Date:11/19/2009)...ulti-institutional effort co-led by three Cold Spr... today in publication of a landmark series of pape...nted detail the DNA sequence of maize ( Zea mays )...h American consumers, is one of the world,s most i... crop grown in the United States, representing $47...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as Of Counsel 55171 1Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as Of Counsel 55171 2Decorated Trial Attorney Conard Metcalf Joins Simmons Firm as Of Counsel 55171 3Blood Mercury Levels Rising Among U S Women 55169 1Blood Mercury Levels Rising Among U S Women 55169 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 1FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 3FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 4FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 5FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 6FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 7FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 8FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 9FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 10
...k species, there seems to be super-sized confusion...at the University of New Hampshire, one thing is c...ish shark populations in the past two decades. ,... many of the three-foot-long sharks that the yello...However, fishery management plans have set quotas ...
... know that the mental clarity lost because of a fe...od night,s rest. Now, UT Southwestern Medical Cent...hanism that regulates the brain,s ability to menta...with mice, they found that a molecule called an ad... animals to attain adequate levels of slow-wave ac...
...nd security, law enforcement and other first-respo...ing encouraged to attend the 2009 Force Protection...rginia this May 19-21. , , Nearly 600 exhibits wi...t, just south of Marine Corps Base, Quantico, VA. ...demonstrations will be at ranges on the Marine Cor...
Other Biology News:UNH researchers studying spiny dogfish, Gulf of Maine's mini shark 2UNH researchers studying spiny dogfish, Gulf of Maine's mini shark 3UT Southwestern researchers identify molecule that helps the sleep-deprived to mentally rebound 2Demonstration Targets Terrorism 2
(Date:11/19/2009)...9 /PRNewswire/ - Aegera Therapeutics Inc. announce...mized Phase 2B study of AEG35156, a targeted antis...iple oncology indications. ,, The study, entitl...X-Linked Inhibitor of Apoptosis (XIAP) Antisense A...bine and Idarubicin in AML Following Failure of a ...
(Date:11/18/2009)...v. 18 Marrone Bio Innovations (MBI...ercialization of effective and environmentally res...it has been named an IC20 company by the Investors...tional angel investing group. ,, Companies name...rding results for all stakeholders, including inve...
(Date:11/18/2009)...., Nov. 18 Sangamo BioSc... data from the University of Pennsylvania investig...inc finger nuclease (ZFN) based product, SB-728-T,...isclosed on the internet. ,, Data were presente...vania School of Medicine from a single subject tre...
(Date:11/18/2009)...Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences In...oduct development company that identifies and adva...ed products at various stages of development, anno...umab were presented today in a poster at the 2009 ...eutics conference in Boston, Massachusetts. The re...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3
...on,(Nasdaq: RGEN ) announced today that the Compa.... Herlihy, Ph.D., will present at the 2008 UBS,Glo...er 24, 2008 at 1:00,p.m. EDT at the Grand Hyatt Ho...dio-webcast of the presentation will be available ... and will be archived for 30 days,following the p...
...daq: DNDN ) today announced that Mitchell H. Gold...endreon, will present a company update at the,UBS ...on Monday, September,22, 2008 at 1:30 p.m. ET., A...cessible through the,Investor Relations section of...f you are unable to listen to the live webcast,it ...
...ositions company as it expands its ...Calif., Sept. 17 Tethys Bioscience, Inc.,announce... of West,Sacramento, Calif. The acquisition will b...sing conditions. Financial terms were not disclose...abolite profiling,technology with Tethys, proven e...
Other Biology Technology:Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT 2Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT 3Tethys Bioscience Announces Acquisition of Lipomics Technologies 2Tethys Bioscience Announces Acquisition of Lipomics Technologies 3
Goat Anti-DRAK 2 Polyclonal Antibody, Unconjugated from Novus Biologicals
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
...tain a proprietary high-performance desalting resi...salting and protein-recovery characteristics compa...s containing as low as 25 g/ml of protein can be p...nd > 95% retention of salts and other small molecu...
... antibody detects an ~185 kDa protein, correspondi...orylated at tyrosine 1248 on SDS-PAGE immunoblots....rbed against the non-phosphorylated peptide to rem...ted form of the protein. In cell lines where EGFR...
Biology Products: